Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03882840 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 30 to 60v5 Show 5 more changesShow less
    • Primary completion date: Jan 1, 2026 to Jan 1, 2028
    • Study completion date: Jan 1, 2029 to Jan 1, 2035
    • Interventions: NK cell therapy (Biological) to ITNK cell therapy (Biological)
    • Study description revised
    • Study arms: 1 to 2
  2. Primary completion date: Jan 1, 2021 to Jan 1, 2026
    • Study completion date: Jan 1, 2022 to Jan 1, 2029
    v4
  3. Study completion date: Jan 1, 2021 to Jan 1, 2022v3
  4. Primary endpoint revised
    • Study description expanded, about 53 words
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
T effector cells and NK cells have mutual compensatory killing functions on various of cancer types. For those cancers that have no available targets for CAR-T cell generations, we established potent T cell-like NK cells (ITNK) with a specific conversion protocol for the T cells from the patient, to perform anti-cancer therapy, especially for those cancers that are lack of MHC-I molecule expression. We have finished pre-clinical investigations for the ITNK or CAR-ITNK cell therapy and scheduled to start a clinical phase I study.
Trial Details
NCT Number NCT03882840
Lead Sponsor Second Affiliated Hospital of Guangzhou Medical University
Collaborators: Hunan Zhaotai Yongren Medical Innovation Co. Ltd.
Conditions
(from sponsor)		 Anti-cancer Cell Immunotherapy, T Cell and NK Cell
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov